A Phase 2 interventional study of Placebo and Dapirolizumab pegol (DZP) in Systemic Lupus Erythematosus (SLE), sponsored by UCB Biopharma S.P.R.L.. Completed at 71 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-30.
Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 10th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 2, and was the 16th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
Candid Therapeutics · Sites in China
Ages 18–75
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 20 more countries
Ages 16+
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 21 more countries
Ages 16+
UCB Biopharma SRL
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 9
First in 2005; this study’s year is marked. 1 started in 2016.
This study's enrollment of 182 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma S.P.R.L., one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma S.P.R.L. is the lead sponsor of 48 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 12 (80%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence for at least 1 of the following SLE markers:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo in a specified sequence for a total of 24 weeks
Drug: Placebo
Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
Drug: Dapirolizumab pegol (DZP)
Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
Drug: Dapirolizumab pegol (DZP)
Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
Drug: Dapirolizumab pegol (DZP)
Solution for infusion, 0,9% saline
Solution for infusion
Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24
The primary efficacy variable was assessed by establishing if there was a dose response relationship between BICLA response at Week 24 and dose, using Multiple Comparison Procedure - Modelling (MCP-Mod). Four candidate dose-response models were evaluated: a linear model, a logistic model, and 2 Emax models, and the MCP-Mod methodology controlled for multiplicity. BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.
Time frame: Week 24
The Percentage of Participants With BICLA (mNRI) Response in the Individual Dose Groups at Week 24
BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.
Time frame: Week 24
Percentage of Participants With at Least One Adverse Events (AEs)
An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.
Time frame: From Baseline (Week 1) until end of the study (Week 48)
Percentage of Participants With a Serious Adverse Event (SAE)
A Serious Adverse Event (SAE) must have met 1 or more of the following criteria: * Death * Life threatening * Significant or persistent disability/incapacity * Congenital anomaly/birth defect (including that occurring in a fetus) * Important medical event that, based upon appropriate medical judgment, may have jeopardized the study participant, and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious * Initial inpatient hospitalization or prolongation of hospitalization.
Time frame: From Baseline (Week 1) until end of the study (Week 48)
Percentage of Participants With at Least One Adverse Events (AEs) of Interest
Adverse events of interest (AEOI) were identified by the Investigator based on definitions per protocol, documented on the electronic Case Report Form (eCRF), adequately monitored, and source controlled. AEOI (regardless of seriousness): * Moderate to severe infections, including opportunistic infections and tuberculosis (TB) * Infusion reactions (including hypersensitivity and anaphylaxis) * Thromboembolic events (including but not limited to cardiovascular events, stroke, myocardial infarction, pulmonary embolism, and deep vein thrombosis) * Prespecified neurological events: severe and/or serious headache, positional headache, cranial nerve dysfunction, or signs and symptoms of meningitis (photophobia, neck stiffness) * Malignancies.
Time frame: From Baseline (Week 1) until end of the study (Week 48)
Percentage of Participants Who Permanently Withdrew of Study Drug Due to an Adverse Event (AE)
An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.
Time frame: From Baseline (Week 1) until end of the study (Week 48)
Mean Change From Baseline in Systolic Blood Pressure
Blood pressure was measured in millimetre of mercury (mmHg).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Diastolic Blood Pressure
Blood pressure was measured in millimetre of mercury (mmHg).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Pulse Rate
Pulse Rate was measured in beats per minute (beats/min).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Temperature
Temperature was measured in Grad Celsius (°C).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Weight
Weight was measured in kilograms (kg).
Time frame: Baseline (Week 1), Week 4, Week 8, Week 12, Week 16, and Week 20
Mean Change From Baseline in Height
Height was measured in centimeters (cm).
Time frame: From Baseline (Week 1) to Week 48
Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormal Findings
Twelve-lead ECG assessments should have been performed prior to dosing (if applicable) and prior to obtaining pharmacokinetic (PK) or other laboratory samples. Electrocardiograms were recorded digitally and read by the Investigator for recording in the electronic Case Report Form (eCRF).
Time frame: Screening, Week 4, Week 24, Week 28 and Week 48
Mean Change From Baseline in Hemoglobin
Hemoglobin was measured in grams per liter (g/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Hematocrit
Hematocrit was measured in volume percentage (%) of red blood cells in blood.
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Erythrocytes
Erythrocytes was measured in number of erythrocytes per liter (10\^12/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Erythrocytes Mean Corpuscular Volume
Erythrocytes Mean Corpuscular Volume was measured in femtolitres (fL).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration was measured in grams per liter (g/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
Erythrocytes Mean Corpuscular Hemoglobin was measured in picograms (pg).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Leukocytes
Leukocytes was measured in number of leukocytes per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Basophils
Basophils was measured in number of basophils per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Basophils/Leukocytes
Basophils/Leukocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Eosinophils
Eosinophils was measured in number of eosinophils per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Eosinophils/Leukocytes
Eosinophils/Leukocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Lymphocytes
Lymphocytes was measured in number of lymphocytes per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Lymphocytes/Leukocytes
Lymphocytes/Leukocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Monocytes
Monocytes was measured in number of monocytes per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Monocytes/Leukocytes
Monocytes/Leukocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Neutrophils
Neutrophils was measured in number of neutrophils per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Neutrophils/Leukocytes
Neutrophils/Leukocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Platelets
Platelets was measured in number of platelets per liter (10\^9/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Cluster of Differentiation 3 (CD3)
Cluster of differentiation 3 (CD3) was measured in cells per microliter (cells/µL).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in CD3/Lymphocytes
CD3/Lymphocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Cluster of Differentiation 19 (CD19)
Cluster of differentiation 19 (CD19) was measured in cells per microliter (cells/µL).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in CD19/Lymphocytes
CD19/Lymphocytes was measured in percentages (%).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Aspartate Aminotransferase
Aspartate Aminotransferase was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Alanine Aminotransferase
Alanine Aminotransferase was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Alkaline Phosphatase
Alkaline Phosphatase was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Gamma Glutamyl Transferase
Gamma Glutamyl Transferase was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Bilirubin
Bilirubin was measured in micromols per liter (µmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Direct Bilirubin
Direct Bilirubin was measured in micromols per liter (µmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Lactate Dehydrogenase
Lactate Dehydrogenase was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Creatinine
Creatinine was measured in micromols per liter (µmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Urea Nitrogen
Urea Nitrogen was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Sodium
Sodium was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Potassium
Potassium was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Calcium
Calcium was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Phosphate
Phosphate was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Cholesterol
Cholesterol was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Triglycerides
Triglycerides was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Protein
Protein was measured in grams per liter (g/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Albumin
Albumin was measured in grams per liter (g/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Glucose
Glucose was measured in millimoles per liter (mmol/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Lipase, Pancreatic
Lipase, Pancreatic was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Creatine Kinase
Creatine Kinase was measured in units per liter (U/L).
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in pH
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Erythrocytes (/HPF)
Time frame: From Baseline (Week 1) to Week 48
Mean Change From Baseline in Leukocytes (/HPF)
Time frame: From Baseline (Week 1) to Week 48
The study started to enroll patients in June 2016 and concluded in November 2018.
| Milestone | SOC + Placebo iv Q4W | SOC + DZP 6mg/kg iv Q4W | SOC + DZP 24mg/kg iv Q4W | SOC + DZP 45mg/kg iv Q4W |
|---|---|---|---|---|
| Started | 45 | 45 | 45 | 47 |
| Completed week 24 | 44 | 45 | 44 | 45 |
| Finished wk24 began observational period | 44 | 44 | 44 | 45 |
| Completed | 44 | 44 | 44 | 45 |
| Not completed | 1 | 1 | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 2 |
| Withdrew: Consent withdrawal after week 24 | 0 | 1 | 0 | 0 |
| Milestone | SOC + Placebo iv Q4W | SOC + DZP 6mg/kg iv Q4W | SOC + DZP 24mg/kg iv Q4W | SOC + DZP 45mg/kg iv Q4W |
|---|---|---|---|---|
| Started | 44 | 44 | 44 | 45 |
| Completed | 38 | 43 | 41 | 42 |
| Not completed | 6 | 1 | 3 | 3 |
| Withdrew: Lost to follow-up | 2 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 0 | 2 | 2 |
| Withdrew: Patient moved out of state | 0 | 1 | 0 | 0 |
The primary efficacy variable was assessed by establishing if there was a dose response relationship between BICLA response at Week 24 and dose, using Multiple Comparison Procedure - Modelling (MCP-Mod). Four candidate dose-response models were evaluated: a linear model, a logistic model, and 2 Emax models, and the MCP-Mod methodology controlled for multiplicity. BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.
| percentage of participants | SOC + Placebo iv Q4W (FAS) | SOC + DZP 6mg/kg iv Q4W (FAS) | SOC + DZP 24mg/kg iv Q4W (FAS) | SOC + DZP 45mg/kg iv Q4W (FAS) |
|---|---|---|---|---|
| Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response Across 3 Doses of Dapirolizumab Pegol (DZP) and Placebo (PBO) at Week 24 | 0 | 0 | 0 | 0 |
BICLA response was defined as meeting all of the following criteria: 1. BILAG 2004 improvement: A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤ 1 new B. 2. No worsening in Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K), defined as no increase in SLEDAI-2K total score. 3. No worsening in Physician's Global Assessment of Disease Activity (PGA), defined as \< 10 millimeter (mm) increase on a 100 mm visual analog scale (VAS). 4. No disallowed changes in concomitant medications, mainly including increases in corticosteroids, immunosuppressants, and antimalarials.
| percentage of participants | SOC + Placebo iv Q4W (FAS) | SOC + DZP 6mg/kg iv Q4W (FAS) | SOC + DZP 24mg/kg iv Q4W (FAS) | SOC + DZP 45mg/kg iv Q4W (FAS) |
|---|---|---|---|---|
| The Percentage of Participants With BICLA (mNRI) Response in the Individual Dose Groups at Week 24 | 37.2 | 48.8 | 54.5 | 52.2 |
An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.
| percentage of participants | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Events (AEs) | 66.7 | 66.7 | 82.2 | 74.5 |
A Serious Adverse Event (SAE) must have met 1 or more of the following criteria: * Death * Life threatening * Significant or persistent disability/incapacity * Congenital anomaly/birth defect (including that occurring in a fetus) * Important medical event that, based upon appropriate medical judgment, may have jeopardized the study participant, and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious * Initial inpatient hospitalization or prolongation of hospitalization.
| percentage of participants | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Percentage of Participants With a Serious Adverse Event (SAE) | 13.3 | 11.1 | 13.3 | 10.6 |
Adverse events of interest (AEOI) were identified by the Investigator based on definitions per protocol, documented on the electronic Case Report Form (eCRF), adequately monitored, and source controlled. AEOI (regardless of seriousness): * Moderate to severe infections, including opportunistic infections and tuberculosis (TB) * Infusion reactions (including hypersensitivity and anaphylaxis) * Thromboembolic events (including but not limited to cardiovascular events, stroke, myocardial infarction, pulmonary embolism, and deep vein thrombosis) * Prespecified neurological events: severe and/or serious headache, positional headache, cranial nerve dysfunction, or signs and symptoms of meningitis (photophobia, neck stiffness) * Malignancies.
| percentage of participants | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Percentage of Participants With at Least One Adverse Events (AEs) of Interest | 24.4 | 26.7 | 28.9 | 25.5 |
An AE was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An adverse event (AE) was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AEs that occurred during the study were considered related unless clearly unrelated.
| percentage of participants | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Percentage of Participants Who Permanently Withdrew of Study Drug Due to an Adverse Event (AE) | 8.9 | 0 | 4.4 | 4.3 |
Blood pressure was measured in millimetre of mercury (mmHg).
| mmHg | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 3.3 ± 12.9 | 5.1 ± 10.5 | 0.7 ± 10.7 | 3.2 ± 9.9 |
| Week 4 | 0.6 ± 10.8 | 1.0 ± 7.9 | -2.0 ± 8.9 | 0.6 ± 12.4 |
| Week 6 | 0.3 ± 11.5 | 4.0 ± 9.9 | 2.3 ± 11.0 | 2.4 ± 10.6 |
| Week 8 | 0.5 ± 12.4 | 3.3 ± 12.6 | -2.4 ± 9.9 | -0.7 ± 11.9 |
| Week 12 | -0.7 ± 10.1 | 3.2 ± 10.5 | -3.0 ± 11.8 | 0.8 ± 9.2 |
| Week 16 | 2.1 ± 12.3 | 2.1 ± 11.6 | -2.8 ± 10.6 | 0.9 ± 11.1 |
| Week 20 | 1.6 ± 9.9 | 2.6 ± 9.8 | -1.7 ± 12.3 | 1.5 ± 11.3 |
| Week 24 | -0.7 ± 14.3 | 1.1 ± 13.1 | 0.3 ± 11.0 | 3.6 ± 9.3 |
| Week 28 | 1.8 ± 12.3 | 3.7 ± 13.1 | 0.9 ± 10.5 | 2.5 ± 11.8 |
| Week 32 | 2.2 ± 11.1 | 3.0 ± 13.2 | 0.4 ± 11.3 | 4.3 ± 13.7 |
| Week 36 | 2.1 ± 11.0 | 3.1 ± 12.6 | 0.2 ± 10.5 | 2.4 ± 12.9 |
| Week 40 | -1.0 ± 14.1 | 6.2 ± 12.9 | -2.0 ± 11.7 | 2.5 ± 11.3 |
| Week 44 | 0.1 ± 12.6 | 3.3 ± 14.1 | 1.3 ± 10.4 | 4.2 ± 11.8 |
| Week 48 | -1.5 ± 11.5 | 4.9 ± 14.3 | 0.1 ± 10.2 | 4.4 ± 12.0 |
Blood pressure was measured in millimetre of mercury (mmHg).
| mmHg | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 2.1 ± 10.5 | 1.4 ± 8.6 | 1.5 ± 9.3 | 2.4 ± 8.2 |
| Week 4 | -0.7 ± 7.8 | -1.5 ± 6.3 | -1.7 ± 8.2 | -0.1 ± 8.3 |
| Week 6 | 1.0 ± 10.0 | 1.5 ± 8.6 | 1.8 ± 10.0 | 1.9 ± 7.9 |
| Week 8 | 1.1 ± 9.2 | 0.4 ± 9.1 | 0.1 ± 8.6 | 1.0 ± 8.0 |
| Week 12 | -0.9 ± 8.4 | -0.3 ± 6.9 | -2.2 ± 9.6 | -0.3 ± 6.9 |
| Week 16 | -0.3 ± 8.9 | -1.3 ± 7.6 | -0.7 ± 9.5 | -0.1 ± 7.0 |
| Week 20 | 1.5 ± 8.1 | -1.1 ± 8.7 | -0.7 ± 9.6 | 0.9 ± 8.8 |
| Week 24 | 1.9 ± 11.2 | 1.6 ± 8.7 | 2.3 ± 10.7 | 0.6 ± 8.7 |
| Week 28 | 1.5 ± 9.1 | -0.2 ± 8.8 | 1.4 ± 8.4 | 2.5 ± 8.4 |
| Week 32 | 2.3 ± 10.1 | 2.8 ± 9.3 | 0.7 ± 10.2 | 2.3 ± 8.1 |
| Week 36 | 3.4 ± 9.8 | 1.4 ± 10.2 | 1.4 ± 8.4 | 2.2 ± 8.0 |
| Week 40 | 1.0 ± 9.2 | 2.6 ± 7.6 | 0.5 ± 9.9 | 3.6 ± 8.8 |
| Week 44 | 0.8 ± 10.2 | 1.5 ± 8.1 | 0.4 ± 9.4 | 2.2 ± 10.3 |
| Week 48 | 1.4 ± 9.0 | 2.3 ± 8.8 | 1.1 ± 9.4 | 2.4 ± 8.6 |
Pulse Rate was measured in beats per minute (beats/min).
| beats/min | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.2 ± 8.3 | 0.2 ± 10.4 | 2.3 ± 9.7 | -0.9 ± 10.4 |
| Week 4 | 1.7 ± 9.6 | 1.5 ± 8.0 | 0.4 ± 8.4 | -3.3 ± 9.7 |
| Week 6 | -0.7 ± 10.2 | 0.1 ± 8.5 | 0.8 ± 8.9 | -0.6 ± 8.8 |
| Week 8 | 1.3 ± 9.0 | 0.3 ± 9.2 | 1.4 ± 10.2 | -2.6 ± 10.2 |
| Week 12 | 0.6 ± 10.3 | 1.1 ± 9.8 | -0.3 ± 10.4 | -1.5 ± 9.7 |
| Week 16 | -0.8 ± 9.2 | 0.3 ± 8.9 | 0.9 ± 10.7 | -1.6 ± 10.6 |
| Week 20 | 0.3 ± 10.6 | 1.1 ± 9.9 | 0.8 ± 9.5 | 0.4 ± 6.6 |
| Week 24 | -1.5 ± 10.7 | 0.8 ± 10.9 | -0.3 ± 10.2 | -1.0 ± 8.7 |
| Week 28 | 0.6 ± 11.8 | 1.3 ± 10.9 | 0.0 ± 9.2 | 0.6 ± 8.8 |
| Week 32 | 0.4 ± 9.8 | 1.3 ± 10.9 | 0.8 ± 11.4 | -2.1 ± 11.0 |
| Week 36 | -0.7 ± 10.9 | 0.2 ± 8.3 | 0.7 ± 10.4 | -0.2 ± 9.8 |
| Week 40 | -0.1 ± 10.9 | -0.1 ± 9.8 | 0.6 ± 10.2 | -1.3 ± 9.6 |
| Week 44 | -0.2 ± 10.2 | -0.1 ± 9.8 | 0.3 ± 11.7 | -0.6 ± 8.9 |
| Week 48 | -0.2 ± 11.1 | -0.7 ± 10.6 | -0.9 ± 11.9 | -2.0 ± 7.7 |
Temperature was measured in Grad Celsius (°C).
| Temperature (C) | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.1 ± 0.4 | 0.0 ± 0.3 | 0.1 ± 0.5 | 0.0 ± 0.4 |
| Week 4 | -0.1 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.3 |
| Week 6 | -0.2 ± 0.5 | 0.0 ± 0.4 | 0.1 ± 0.5 | 0.0 ± 0.5 |
| Week 8 | -0.1 ± 0.4 | -0.1 ± 0.3 | 0.0 ± 0.4 | 0.0 ± 0.4 |
| Week 12 | -0.1 ± 0.4 | -0.1 ± 0.4 | 0.0 ± 0.3 | 0.0 ± 0.4 |
| Week 16 | -0.1 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.3 |
| Week 20 | -0.1 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.5 |
| Week 24 | -0.1 ± 0.5 | 0.0 ± 0.4 | 0.1 ± 0.5 | 0.0 ± 0.4 |
| Week 28 | 0.0 ± 0.4 | 0.0 ± 0.4 | 0.1 ± 0.5 | 0.1 ± 0.5 |
| Week 32 | 0.0 ± 0.4 | 0.0 ± 0.4 | 0.1 ± 0.5 | 0.0 ± 0.4 |
| Week 36 | -0.1 ± 0.3 | 0.0 ± 0.6 | 0.0 ± 0.4 | 0.1 ± 0.4 |
| Week 40 | 0.0 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.5 | 0.1 ± 0.3 |
| Week 44 | 0.0 ± 0.6 | 0.0 ± 0.5 | 0.1 ± 0.4 | 0.0 ± 0.4 |
| Week 48 | -0.1 ± 0.4 | 0.0 ± 0.4 | 0.0 ± 0.5 | 0.0 ± 0.4 |
Weight was measured in kilograms (kg).
| kg | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 4 | 0.0 ± 1.0 | 0.2 ± 1.0 | 0.4 ± 0.9 | 0.3 ± 1.2 |
| Week 8 | 0.3 ± 1.9 | 0.6 ± 1.4 | 0.6 ± 1.8 | 0.4 ± 1.8 |
| Week 12 | 0.4 ± 2.3 | 0.5 ± 1.6 | 0.5 ± 2.0 | 0.6 ± 2.3 |
| Week 16 | 0.3 ± 2.3 | 0.7 ± 2.3 | 0.8 ± 2.3 | 0.5 ± 2.4 |
| Week 20 | 0.3 ± 2.4 | 0.7 ± 2.6 | 1.0 ± 2.6 | 0.5 ± 2.8 |
Height was measured in centimeters (cm).
| cm | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Mean Change From Baseline in Height | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Twelve-lead ECG assessments should have been performed prior to dosing (if applicable) and prior to obtaining pharmacokinetic (PK) or other laboratory samples. Electrocardiograms were recorded digitally and read by the Investigator for recording in the electronic Case Report Form (eCRF).
| Participants | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Screening | 8 | 11 | 6 | 6 |
| Week 4 | 11 | 12 | 7 | 10 |
| Week 24 | 9 | 7 | 6 | 10 |
| Week 28 | 1 | 0 | 0 | 0 |
| Week 48 | 8 | 7 | 11 | 9 |
Hemoglobin was measured in grams per liter (g/L).
| g/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.4 ± 6.4 | -1.8 ± 5.8 | -0.7 ± 6.9 | -0.7 ± 6.8 |
| Week 4 | -1.0 ± 7.2 | -0.7 ± 7.7 | -1.4 ± 8.6 | -0.8 ± 5.8 |
| Week 8 | -0.3 ± 7.3 | -1.9 ± 7.9 | -1.9 ± 8.6 | -1.3 ± 7.4 |
| Week 12 | -0.5 ± 9.5 | -0.5 ± 8.5 | -0.5 ± 10.1 | 0.2 ± 8.3 |
| Week 16 | 0.3 ± 10.4 | -0.3 ± 10.0 | -0.8 ± 10.6 | -2.7 ± 8.3 |
| Week 20 | -0.7 ± 11.5 | 0.3 ± 9.9 | -0.5 ± 10.1 | -2.4 ± 7.2 |
| Week 24 | -0.4 ± 9.7 | -0.7 ± 11.2 | -0.7 ± 10.5 | -2.9 ± 8.1 |
| Week 28 | 0.7 ± 10.6 | -3.4 ± 11.0 | 0.0 ± 14.1 | -3.1 ± 9.5 |
| Week 32 | 1.6 ± 12.5 | -1.3 ± 9.8 | 1.0 ± 12.5 | -1.3 ± 9.6 |
| Week 40 | 0.7 ± 13.5 | -0.3 ± 13.5 | 1.9 ± 14.9 | 1.1 ± 11.0 |
| Week 48 | -0.5 ± 14.3 | -1.5 ± 11.6 | 0.9 ± 12.5 | -0.7 ± 10.0 |
Hematocrit was measured in volume percentage (%) of red blood cells in blood.
| volume % of red blood cells | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.42 ± 2.52 | -0.25 ± 2.26 | -0.32 ± 2.37 | 0.00 ± 2.71 |
| Week 4 | -0.46 ± 2.29 | -0.17 ± 2.75 | -0.79 ± 2.92 | -0.11 ± 2.31 |
| Week 8 | -0.27 ± 2.23 | -0.12 ± 2.94 | -0.86 ± 2.72 | -0.42 ± 2.31 |
| Week 12 | -0.23 ± 2.67 | -0.13 ± 2.72 | -0.32 ± 3.39 | -0.02 ± 2.54 |
| Week 16 | -0.12 ± 2.86 | 0.05 ± 3.25 | -0.57 ± 3.32 | -0.84 ± 2.95 |
| Week 20 | -0.41 ± 3.20 | 0.13 ± 2.99 | -0.42 ± 3.32 | -0.80 ± 2.83 |
| Week 24 | -0.09 ± 2.61 | -0.40 ± 3.19 | -0.29 ± 3.14 | -0.76 ± 2.33 |
| Week 28 | 0.03 ± 2.98 | -1.02 ± 3.23 | -0.22 ± 3.99 | -0.89 ± 2.47 |
| Week 32 | 0.29 ± 2.89 | -0.62 ± 2.86 | 0.17 ± 3.43 | -0.21 ± 2.82 |
| Week 40 | -0.20 ± 3.32 | -0.24 ± 4.37 | 0.58 ± 4.11 | 0.37 ± 2.72 |
| Week 48 | -0.59 ± 3.51 | -0.37 ± 3.58 | -0.08 ± 3.21 | -0.11 ± 2.54 |
Erythrocytes was measured in number of erythrocytes per liter (10\^12/L).
| 10^12 erythrocytes per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.004 ± 0.246 | -0.035 ± 0.237 | -0.032 ± 0.223 | -0.028 ± 0.237 |
| Week 4 | -0.080 ± 0.243 | -0.018 ± 0.293 | -0.052 ± 0.273 | -0.033 ± 0.210 |
| Week 8 | -0.039 ± 0.224 | -0.039 ± 0.280 | -0.069 ± 0.262 | -0.044 ± 0.242 |
| Week 12 | -0.024 ± 0.271 | 0.014 ± 0.292 | -0.010 ± 0.267 | 0.019 ± 0.226 |
| Week 16 | -0.002 ± 0.312 | 0.041 ± 0.360 | 0.000 ± 0.302 | -0.051 ± 0.265 |
| Week 20 | -0.029 ± 0.333 | 0.062 ± 0.309 | -0.001 ± 0.325 | -0.047 ± 0.302 |
| Week 24 | 0.005 ± 0.308 | 0.036 ± 0.312 | 0.013 ± 0.319 | -0.038 ± 0.240 |
| Week 28 | 0.018 ± 0.340 | -0.040 ± 0.304 | 0.019 ± 0.346 | -0.050 ± 0.270 |
| Week 32 | 0.048 ± 0.320 | 0.001 ± 0.284 | 0.032 ± 0.289 | 0.027 ± 0.277 |
| Week 40 | -0.005 ± 0.343 | 0.042 ± 0.382 | 0.054 ± 0.368 | 0.060 ± 0.256 |
| Week 48 | -0.024 ± 0.332 | -0.018 ± 0.295 | 0.017 ± 0.299 | -0.028 ± 0.245 |
Erythrocytes Mean Corpuscular Volume was measured in femtolitres (fL).
| Femtolitres (fL) | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 1.01 ± 2.28 | 0.24 ± 2.40 | -0.09 ± 2.66 | 0.45 ± 2.96 |
| Week 4 | 0.60 ± 2.35 | 0.08 ± 2.66 | -0.68 ± 2.10 | 0.40 ± 3.02 |
| Week 8 | 0.23 ± 3.48 | -0.30 ± 5.36 | -0.54 ± 2.85 | -0.16 ± 2.79 |
| Week 12 | 0.06 ± 3.57 | -0.52 ± 3.44 | -0.55 ± 4.67 | -0.57 ± 3.09 |
| Week 16 | -0.25 ± 3.41 | -0.65 ± 4.38 | -1.38 ± 4.87 | -0.97 ± 3.62 |
| Week 20 | -0.37 ± 3.73 | -0.92 ± 4.58 | -1.00 ± 5.01 | -0.97 ± 3.54 |
| Week 24 | -0.23 ± 3.83 | -1.63 ± 4.07 | -0.92 ± 6.51 | -1.05 ± 4.00 |
| Week 28 | -0.33 ± 3.61 | -1.40 ± 4.61 | -0.96 ± 6.46 | -1.21 ± 4.91 |
| Week 32 | -0.27 ± 4.45 | -1.33 ± 4.32 | -0.45 ± 6.81 | -1.06 ± 4.69 |
| Week 40 | -0.36 ± 5.34 | -1.46 ± 4.72 | 0.07 ± 6.27 | -0.24 ± 4.85 |
| Week 48 | -0.98 ± 5.34 | -0.50 ± 4.97 | -0.63 ± 6.92 | 0.34 ± 4.31 |
Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration was measured in grams per liter (g/L).
| g/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -2.3 ± 9.8 | -2.6 ± 10.9 | 0.7 ± 9.8 | -1.9 ± 10.1 |
| Week 4 | 1.4 ± 8.7 | -0.9 ± 10.1 | 2.7 ± 8.6 | -1.2 ± 12.5 |
| Week 8 | 1.7 ± 11.5 | -3.8 ± 13.4 | 2.1 ± 8.2 | -0.1 ± 11.5 |
| Week 12 | 0.5 ± 11.1 | -0.6 ± 10.7 | 0.6 ± 12.3 | 0.5 ± 12.7 |
| Week 16 | 1.6 ± 13.8 | -1.5 ± 10.1 | 2.3 ± 11.3 | -0.2 ± 14.1 |
| Week 20 | 1.6 ± 12.9 | -0.9 ± 11.3 | 2.4 ± 11.2 | 0.4 ± 12.6 |
| Week 24 | 0.0 ± 13.7 | 1.0 ± 13.2 | 0.4 ± 12.8 | -1.2 ± 13.1 |
| Week 28 | 1.6 ± 13.4 | -1.3 ± 14.4 | 1.7 ± 13.8 | -0.6 ± 16.5 |
| Week 32 | 1.7 ± 18.9 | 1.1 ± 13.8 | 1.2 ± 15.0 | -1.4 ± 16.0 |
| Week 40 | 3.4 ± 17.6 | 0.8 ± 16.5 | 0.1 ± 15.8 | 0.1 ± 15.4 |
| Week 48 | 3.6 ± 17.1 | -0.6 ± 16.2 | 2.9 ± 14.5 | 0.0 ± 13.5 |
Erythrocytes Mean Corpuscular Hemoglobin was measured in picograms (pg).
| Picograms (pg) | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.12 ± 0.71 | -0.18 ± 0.65 | 0.04 ± 0.43 | 0.00 ± 0.47 |
| Week 4 | 0.31 ± 0.63 | -0.06 ± 0.79 | 0.04 ± 0.64 | 0.02 ± 0.65 |
| Week 8 | 0.20 ± 0.87 | -0.25 ± 0.87 | 0.04 ± 0.81 | -0.04 ± 0.74 |
| Week 12 | 0.04 ± 1.08 | -0.25 ± 1.03 | -0.09 ± 1.25 | -0.12 ± 0.90 |
| Week 16 | 0.03 ± 1.43 | -0.36 ± 1.31 | -0.20 ± 1.52 | -0.31 ± 1.19 |
| Week 20 | 0.00 ± 1.49 | -0.39 ± 1.40 | -0.10 ± 1.63 | -0.26 ± 1.24 |
| Week 24 | -0.13 ± 1.57 | -0.43 ± 1.39 | -0.25 ± 1.96 | -0.44 ± 1.42 |
| Week 28 | 0.01 ± 1.68 | -0.55 ± 1.45 | -0.15 ± 2.09 | -0.44 ± 1.68 |
| Week 32 | 0.01 ± 2.12 | -0.33 ± 1.28 | -0.06 ± 2.39 | -0.48 ± 1.63 |
| Week 40 | 0.17 ± 2.50 | -0.40 ± 1.30 | 0.03 ± 2.32 | -0.09 ± 2.00 |
| Week 48 | 0.02 ± 2.58 | -0.21 ± 1.48 | 0.06 ± 2.55 | 0.10 ± 1.90 |
Leukocytes was measured in number of leukocytes per liter (10\^9/L).
| 10^9 leukocytes per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.34 ± 2.45 | 0.27 ± 1.23 | 0.49 ± 1.46 | 0.20 ± 1.62 |
| Week 4 | 0.10 ± 1.88 | 0.27 ± 1.63 | 0.25 ± 1.47 | 0.52 ± 2.11 |
| Week 8 | -0.25 ± 2.12 | 0.46 ± 1.41 | -0.05 ± 1.50 | -0.10 ± 1.65 |
| Week 12 | -0.27 ± 1.80 | 0.18 ± 1.73 | 0.17 ± 2.00 | 0.23 ± 2.01 |
| Week 16 | -0.31 ± 2.18 | 0.13 ± 1.55 | 0.21 ± 1.69 | -0.20 ± 2.12 |
| Week 20 | -0.24 ± 2.27 | -0.06 ± 1.59 | -0.22 ± 1.74 | 0.30 ± 2.61 |
| Week 24 | -0.22 ± 2.41 | -0.12 ± 1.83 | -0.14 ± 1.75 | -0.34 ± 1.97 |
| Week 28 | 0.05 ± 2.04 | 0.06 ± 1.93 | 0.26 ± 2.04 | -0.58 ± 1.70 |
| Week 32 | -0.14 ± 2.20 | 0.08 ± 1.64 | 0.19 ± 1.67 | -0.44 ± 1.68 |
| Week 40 | 0.17 ± 2.54 | 0.04 ± 1.60 | -0.35 ± 1.49 | -0.49 ± 1.96 |
| Week 48 | -0.49 ± 1.83 | 0.30 ± 1.53 | -0.14 ± 2.06 | -0.62 ± 1.87 |
Basophils was measured in number of basophils per liter (10\^9/L).
| 10^9 basophils per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.01 ± 0.03 | 0.02 ± 0.04 | 0.00 ± 0.03 | 0.00 ± 0.02 |
| Week 4 | 0.01 ± 0.03 | 0.00 ± 0.03 | 0.01 ± 0.04 | 0.00 ± 0.02 |
| Week 8 | 0.01 ± 0.04 | 0.01 ± 0.04 | 0.01 ± 0.03 | 0.00 ± 0.02 |
| Week 12 | 0.01 ± 0.03 | 0.01 ± 0.04 | 0.00 ± 0.03 | 0.00 ± 0.03 |
| Week 16 | 0.01 ± 0.04 | 0.00 ± 0.03 | 0.01 ± 0.03 | 0.00 ± 0.03 |
| Week 20 | 0.00 ± 0.03 | 0.01 ± 0.03 | 0.00 ± 0.03 | 0.00 ± 0.03 |
| Week 24 | 0.00 ± 0.03 | 0.02 ± 0.04 | 0.00 ± 0.03 | 0.00 ± 0.03 |
| Week 28 | 0.02 ± 0.05 | 0.01 ± 0.04 | 0.00 ± 0.02 | 0.00 ± 0.03 |
| Week 32 | 0.00 ± 0.03 | 0.00 ± 0.02 | 0.01 ± 0.03 | 0.00 ± 0.03 |
| Week 40 | 0.00 ± 0.02 | 0.00 ± 0.02 | 0.01 ± 0.03 | 0.00 ± 0.03 |
| Week 48 | 0.00 ± 0.03 | 0.00 ± 0.02 | 0.00 ± 0.03 | 0.01 ± 0.03 |
Basophils/Leukocytes was measured in percentages (%).
| % of Basophils per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.05 ± 0.23 | 0.02 ± 0.20 | -0.05 ± 0.31 | -0.03 ± 0.27 |
| Week 4 | 0.03 ± 0.27 | -0.06 ± 0.26 | -0.01 ± 0.43 | -0.07 ± 0.26 |
| Week 8 | 0.08 ± 0.42 | 0.03 ± 0.32 | 0.00 ± 0.33 | -0.06 ± 0.23 |
| Week 12 | 0.04 ± 0.30 | 0.09 ± 0.48 | 0.00 ± 0.25 | -0.07 ± 0.28 |
| Week 16 | 0.01 ± 0.25 | 0.00 ± 0.28 | -0.02 ± 0.31 | -0.05 ± 0.30 |
| Week 20 | -0.02 ± 0.26 | 0.00 ± 0.27 | -0.07 ± 0.29 | -0.04 ± 0.32 |
| Week 24 | -0.04 ± 0.31 | 0.15 ± 0.44 | -0.03 ± 0.24 | -0.03 ± 0.21 |
| Week 28 | 0.08 ± 0.54 | 0.03 ± 0.29 | 0.00 ± 0.24 | 0.07 ± 0.32 |
| Week 32 | -0.03 ± 0.29 | 0.00 ± 0.23 | 0.01 ± 0.25 | 0.01 ± 0.25 |
| Week 40 | -0.08 ± 0.24 | -0.03 ± 0.25 | 0.07 ± 0.29 | 0.01 ± 0.29 |
| Week 48 | -0.01 ± 0.29 | -0.08 ± 0.21 | 0.02 ± 0.25 | 0.06 ± 0.28 |
Eosinophils was measured in number of eosinophils per liter (10\^9/L).
| 10^9 eosinophils per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.01 ± 0.04 | 0.01 ± 0.06 | 0.00 ± 0.09 | -0.01 ± 0.05 |
| Week 4 | -0.01 ± 0.04 | -0.01 ± 0.06 | 0.00 ± 0.04 | -0.01 ± 0.04 |
| Week 8 | -0.01 ± 0.04 | 0.03 ± 0.16 | 0.00 ± 0.04 | 0.01 ± 0.07 |
| Week 12 | 0.00 ± 0.04 | 0.04 ± 0.20 | 0.02 ± 0.10 | 0.02 ± 0.17 |
| Week 16 | 0.00 ± 0.05 | 0.02 ± 0.11 | 0.01 ± 0.05 | 0.00 ± 0.06 |
| Week 20 | 0.00 ± 0.05 | 0.04 ± 0.24 | 0.01 ± 0.05 | -0.01 ± 0.05 |
| Week 24 | -0.01 ± 0.05 | 0.04 ± 0.15 | 0.02 ± 0.07 | -0.02 ± 0.06 |
| Week 28 | -0.01 ± 0.04 | 0.01 ± 0.07 | 0.01 ± 0.05 | 0.00 ± 0.06 |
| Week 32 | -0.01 ± 0.06 | 0.01 ± 0.10 | 0.01 ± 0.05 | -0.02 ± 0.04 |
| Week 40 | 0.00 ± 0.05 | 0.01 ± 0.06 | 0.02 ± 0.06 | 0.00 ± 0.07 |
| Week 48 | 0.00 ± 0.04 | -0.01 ± 0.05 | 0.00 ± 0.06 | 0.00 ± 0.06 |
Eosinophils/Leukocytes was measured in percentages (%).
| % of Eosinophils per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.19 ± 1.07 | 0.07 ± 0.86 | -0.18 ± 1.13 | -0.29 ± 1.22 |
| Week 4 | -0.32 ± 0.96 | -0.05 ± 1.26 | -0.12 ± 1.01 | -0.26 ± 0.94 |
| Week 8 | -0.05 ± 1.09 | 0.54 ± 2.13 | 0.10 ± 1.11 | 0.22 ± 1.89 |
| Week 12 | 0.18 ± 1.03 | 0.70 ± 3.12 | 0.33 ± 1.68 | 0.05 ± 1.83 |
| Week 16 | 0.06 ± 1.05 | 0.36 ± 1.24 | 0.20 ± 1.40 | -0.11 ± 1.33 |
| Week 20 | 0.04 ± 1.11 | 0.83 ± 3.58 | 0.11 ± 1.24 | -0.39 ± 1.29 |
| Week 24 | 0.11 ± 1.16 | 0.82 ± 2.89 | -0.01 ± 1.22 | 0.06 ± 1.63 |
| Week 28 | 0.06 ± 1.00 | 0.21 ± 1.33 | 0.18 ± 1.02 | -0.03 ± 1.35 |
| Week 32 | 0.02 ± 1.09 | 0.28 ± 1.60 | 0.16 ± 1.13 | -0.20 ± 1.03 |
| Week 40 | -0.10 ± 0.85 | 0.05 ± 1.09 | 0.40 ± 1.23 | -0.09 ± 1.47 |
| Week 48 | 0.09 ± 1.02 | -0.17 ± 1.08 | 0.06 ± 0.90 | 0.24 ± 1.03 |
Lymphocytes was measured in number of lymphocytes per liter (10\^9/L).
| 10^9 lymphocytes per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.03 ± 0.39 | 0.05 ± 0.36 | 0.16 ± 0.29 | 0.24 ± 0.37 |
| Week 4 | -0.04 ± 0.36 | -0.01 ± 0.47 | -0.01 ± 0.41 | 0.23 ± 0.42 |
| Week 8 | -0.15 ± 0.48 | -0.03 ± 0.39 | 0.06 ± 0.46 | 0.14 ± 0.50 |
| Week 12 | -0.06 ± 0.43 | 0.02 ± 0.59 | 0.01 ± 0.42 | 0.21 ± 0.51 |
| Week 16 | -0.09 ± 0.52 | -0.11 ± 0.51 | -0.02 ± 0.47 | 0.04 ± 0.40 |
| Week 20 | -0.14 ± 0.56 | -0.13 ± 0.54 | 0.02 ± 0.39 | 0.13 ± 0.55 |
| Week 24 | -0.11 ± 0.51 | -0.08 ± 0.60 | -0.03 ± 0.45 | 0.05 ± 0.52 |
| Week 28 | -0.04 ± 0.57 | -0.02 ± 0.59 | 0.01 ± 0.53 | 0.03 ± 0.56 |
| Week 32 | -0.11 ± 0.57 | -0.16 ± 0.59 | 0.05 ± 0.45 | -0.02 ± 0.44 |
| Week 40 | -0.11 ± 0.54 | -0.11 ± 0.52 | -0.11 ± 0.43 | -0.03 ± 0.48 |
| Week 48 | -0.19 ± 0.68 | -0.19 ± 0.60 | -0.10 ± 0.44 | -0.02 ± 0.49 |
Lymphocytes/Leukocytes was measured in percentages (%).
| % of Lymphocytes per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -1.88 ± 9.01 | 0.19 ± 6.55 | 1.18 ± 6.09 | 2.61 ± 6.11 |
| Week 4 | -0.88 ± 7.09 | -1.02 ± 6.34 | -1.18 ± 9.93 | 0.97 ± 8.00 |
| Week 8 | -1.98 ± 10.59 | -1.40 ± 7.13 | 0.56 ± 10.20 | 1.97 ± 8.51 |
| Week 12 | 0.21 ± 7.87 | 0.56 ± 10.58 | -0.44 ± 9.90 | 2.46 ± 10.18 |
| Week 16 | -0.91 ± 8.33 | -1.49 ± 7.50 | -1.18 ± 9.65 | 0.12 ± 9.34 |
| Week 20 | -1.97 ± 10.37 | -0.66 ± 6.58 | 0.88 ± 10.69 | 0.71 ± 10.32 |
| Week 24 | -0.75 ± 8.69 | -0.56 ± 7.35 | -0.52 ± 10.55 | 1.85 ± 9.67 |
| Week 28 | -1.18 ± 8.27 | -0.05 ± 8.51 | -0.05 ± 9.97 | 1.61 ± 10.55 |
| Week 32 | -1.59 ± 7.69 | -2.56 ± 6.51 | -0.16 ± 7.70 | 0.70 ± 8.74 |
| Week 40 | -2.60 ± 9.18 | -2.02 ± 5.99 | -1.36 ± 10.12 | 0.33 ± 8.41 |
| Week 48 | -1.46 ± 11.29 | -3.71 ± 7.41 | -0.84 ± 9.42 | 1.69 ± 10.05 |
Monocytes was measured in number of monocytes per liter (10\^9/L).
| 10^9 monocytes per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.01 ± 0.17 | 0.01 ± 0.18 | 0.05 ± 0.14 | 0.01 ± 0.13 |
| Week 4 | 0.01 ± 0.18 | 0.04 ± 0.18 | 0.01 ± 0.14 | 0.06 ± 0.19 |
| Week 8 | -0.03 ± 0.18 | 0.04 ± 0.18 | 0.03 ± 0.16 | 0.02 ± 0.17 |
| Week 12 | -0.01 ± 0.19 | 0.00 ± 0.14 | 0.04 ± 0.18 | 0.06 ± 0.15 |
| Week 16 | -0.01 ± 0.17 | 0.01 ± 0.17 | 0.05 ± 0.18 | 0.03 ± 0.14 |
| Week 20 | -0.03 ± 0.19 | 0.00 ± 0.16 | 0.00 ± 0.13 | 0.05 ± 0.19 |
| Week 24 | 0.00 ± 0.19 | 0.04 ± 0.19 | 0.03 ± 0.17 | 0.00 ± 0.17 |
| Week 28 | 0.00 ± 0.20 | 0.04 ± 0.21 | 0.08 ± 0.19 | 0.02 ± 0.17 |
| Week 32 | -0.01 ± 0.18 | 0.02 ± 0.19 | 0.05 ± 0.23 | -0.01 ± 0.19 |
| Week 40 | 0.03 ± 0.17 | 0.05 ± 0.16 | 0.04 ± 0.16 | -0.01 ± 0.18 |
| Week 48 | -0.02 ± 0.20 | -0.01 ± 0.13 | 0.03 ± 0.15 | -0.02 ± 0.18 |
Monocytes/Leukocytes was measured in percentages (%).
| % of Monocytes per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.87 ± 2.50 | -0.07 ± 2.46 | 0.23 ± 3.03 | -0.37 ± 2.25 |
| Week 4 | 0.26 ± 3.30 | 0.27 ± 2.41 | -0.16 ± 3.11 | -0.24 ± 2.82 |
| Week 8 | -0.21 ± 3.47 | 0.07 ± 3.61 | 0.51 ± 3.83 | 0.08 ± 3.12 |
| Week 12 | 0.07 ± 2.79 | -0.11 ± 2.38 | 0.22 ± 3.37 | 0.45 ± 2.74 |
| Week 16 | 0.06 ± 3.30 | 0.59 ± 2.85 | 0.43 ± 3.31 | 0.28 ± 3.13 |
| Week 20 | -0.27 ± 3.84 | 0.56 ± 3.08 | 0.33 ± 3.81 | 0.43 ± 3.39 |
| Week 24 | 0.06 ± 3.45 | 0.84 ± 2.97 | 0.46 ± 3.00 | 0.41 ± 3.24 |
| Week 28 | -0.24 ± 3.54 | 0.69 ± 3.24 | 0.64 ± 3.67 | 0.94 ± 3.78 |
| Week 32 | -0.08 ± 3.11 | 0.13 ± 2.62 | 0.46 ± 3.91 | -0.03 ± 3.76 |
| Week 40 | 0.49 ± 3.55 | 0.64 ± 2.92 | 0.83 ± 3.69 | 0.59 ± 3.07 |
| Week 48 | -0.04 ± 3.79 | -0.13 ± 2.41 | 0.47 ± 3.82 | 0.29 ± 3.30 |
Neutrophils was measured in number of neutrophils per liter (10\^9/L).
| 10^9 neutrophils per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.28 ± 2.43 | 0.26 ± 1.17 | 0.17 ± 1.33 | -0.01 ± 1.46 |
| Week 4 | 0.07 ± 1.82 | 0.27 ± 1.40 | 0.21 ± 1.64 | 0.23 ± 1.96 |
| Week 8 | -0.13 ± 2.20 | 0.41 ± 1.32 | -0.07 ± 1.53 | -0.20 ± 1.49 |
| Week 12 | -0.24 ± 1.56 | 0.20 ± 1.65 | 0.10 ± 1.94 | -0.01 ± 2.03 |
| Week 16 | -0.22 ± 2.13 | 0.20 ± 1.41 | 0.15 ± 1.61 | -0.20 ± 2.14 |
| Week 20 | -0.07 ± 2.21 | 0.01 ± 1.22 | -0.39 ± 1.69 | 0.09 ± 2.51 |
| Week 24 | -0.12 ± 2.24 | -0.06 ± 1.54 | -0.16 ± 1.77 | -0.38 ± 1.92 |
| Week 28 | 0.04 ± 1.81 | 0.13 ± 1.64 | 0.10 ± 1.91 | -0.62 ± 1.78 |
| Week 32 | -0.07 ± 1.87 | 0.33 ± 1.27 | 0.07 ± 1.54 | -0.40 ± 1.67 |
| Week 40 | 0.16 ± 2.37 | 0.16 ± 1.31 | -0.32 ± 1.57 | -0.41 ± 1.88 |
| Week 48 | -0.29 ± 1.58 | 0.55 ± 1.15 | -0.09 ± 2.02 | -0.54 ± 1.78 |
Neutrophils/Leukocytes was measured in percentages (%).
| % of Neutrophils per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 2.99 ± 10.73 | -0.21 ± 7.94 | -1.20 ± 8.40 | -1.93 ± 8.18 |
| Week 4 | 0.91 ± 9.37 | 0.89 ± 7.82 | 1.47 ± 12.70 | -0.37 ± 10.27 |
| Week 8 | 2.15 ± 12.95 | 0.79 ± 8.80 | -1.17 ± 13.28 | -2.23 ± 10.92 |
| Week 12 | -0.52 ± 9.44 | -1.25 ± 11.78 | -0.12 ± 13.18 | -2.90 ± 12.85 |
| Week 16 | 0.77 ± 11.02 | 0.54 ± 8.50 | 0.56 ± 12.48 | -0.24 ± 12.23 |
| Week 20 | 2.22 ± 13.21 | -0.73 ± 8.42 | -1.25 ± 14.29 | -0.71 ± 13.91 |
| Week 24 | 0.65 ± 11.48 | -1.25 ± 8.74 | 0.10 ± 13.20 | -2.30 ± 12.41 |
| Week 28 | 1.28 ± 10.38 | -0.88 ± 10.56 | -0.77 ± 13.27 | -2.60 ± 13.79 |
| Week 32 | 1.67 ± 9.93 | 2.15 ± 7.42 | -0.47 ± 9.80 | -0.48 ± 12.08 |
| Week 40 | 2.29 ± 11.66 | 1.36 ± 6.95 | 0.07 ± 13.23 | -0.93 ± 11.50 |
| Week 48 | 1.41 ± 13.58 | 4.09 ± 8.40 | 0.30 ± 12.47 | -2.28 ± 12.38 |
Platelets was measured in number of platelets per liter (10\^9/L).
| 10^9 platelets per liter | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 5.9 ± 33.2 | 10.0 ± 40.0 | 1.4 ± 47.5 | -1.0 ± 52.0 |
| Week 4 | -5.2 ± 51.3 | 0.0 ± 32.4 | 4.9 ± 43.8 | 8.1 ± 42.6 |
| Week 8 | 0.2 ± 45.3 | -0.3 ± 40.3 | 3.9 ± 52.0 | -6.4 ± 40.5 |
| Week 12 | -4.3 ± 50.6 | -1.7 ± 38.8 | -2.7 ± 49.0 | 1.8 ± 49.4 |
| Week 16 | 0.7 ± 57.7 | -0.7 ± 40.5 | -1.5 ± 66.7 | -2.3 ± 68.1 |
| Week 20 | 9.2 ± 57.1 | -3.3 ± 43.0 | 0.5 ± 44.6 | 0.8 ± 64.4 |
| Week 24 | 0.2 ± 60.2 | -5.2 ± 43.8 | 2.4 ± 68.6 | 1.7 ± 67.0 |
| Week 28 | 3.6 ± 64.6 | 1.8 ± 52.6 | -5.8 ± 71.9 | 1.5 ± 64.4 |
| Week 32 | 4.0 ± 71.8 | -1.9 ± 55.4 | -4.6 ± 57.5 | 9.9 ± 93.8 |
| Week 40 | 10.3 ± 74.9 | 14.2 ± 52.7 | -8.8 ± 63.2 | -1.5 ± 67.4 |
| Week 48 | 7.1 ± 67.4 | 3.5 ± 58.2 | -9.5 ± 70.9 | -8.8 ± 66.5 |
Cluster of differentiation 3 (CD3) was measured in cells per microliter (cells/µL).
| cells/µL | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 33.0 ± 313.6 | 77.7 ± 383.6 | 106.6 ± 283.1 | 126.9 ± 338.9 |
| Week 4 | -30.6 ± 293.5 | -47.7 ± 504.3 | 24.0 ± 394.9 | 227.2 ± 412.1 |
| Week 8 | -64.7 ± 405.7 | -58.6 ± 422.8 | -20.5 ± 403.2 | 78.3 ± 560.0 |
| Week 12 | -44.2 ± 283.2 | -48.8 ± 452.1 | -57.8 ± 385.1 | 43.7 ± 599.3 |
| Week 16 | -81.9 ± 479.4 | -141.2 ± 516.1 | -4.5 ± 383.2 | -45.4 ± 520.8 |
| Week 20 | -92.7 ± 391.1 | -173.4 ± 490.9 | 5.9 ± 352.9 | -89.9 ± 577.7 |
| Week 24 | -85.8 ± 472.5 | -128.9 ± 569.4 | -88.5 ± 462.1 | -78.3 ± 570.7 |
| Week 28 | -27.6 ± 507.3 | -81.2 ± 652.7 | 46.1 ± 482.2 | 7.4 ± 561.2 |
| Week 32 | -70.9 ± 428.4 | -173.6 ± 565.8 | 18.0 ± 415.0 | -90.5 ± 504.0 |
| Week 40 | -110.5 ± 526.4 | -166.9 ± 542.2 | -1.8 ± 410.7 | 31.7 ± 528.8 |
| Week 48 | -115.6 ± 581.1 | -253.1 ± 637.0 | 36.1 ± 492.3 | 22.3 ± 558.0 |
CD3/Lymphocytes was measured in percentages (%).
| % of CD3 per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.7 ± 6.1 | -0.9 ± 4.6 | -2.0 ± 5.7 | -0.2 ± 7.8 |
| Week 4 | -2.1 ± 7.3 | -0.5 ± 6.0 | -1.9 ± 5.0 | -0.5 ± 6.8 |
| Week 8 | -0.9 ± 6.1 | -1.2 ± 4.8 | -2.6 ± 5.9 | 0.6 ± 9.5 |
| Week 12 | -0.4 ± 5.6 | -1.1 ± 8.2 | -2.4 ± 6.0 | -0.1 ± 9.2 |
| Week 16 | -1.9 ± 5.8 | -1.6 ± 7.8 | -1.9 ± 7.6 | -1.4 ± 7.9 |
| Week 20 | -0.8 ± 5.0 | 0.0 ± 8.6 | -2.3 ± 6.9 | 0.6 ± 9.2 |
| Week 24 | 0.0 ± 6.5 | -0.1 ± 8.8 | -1.8 ± 6.6 | 18.7 ± 114.3 |
| Week 28 | -0.2 ± 6.9 | 0.2 ± 8.3 | -2.9 ± 7.2 | 0.9 ± 10.2 |
| Week 32 | -1.3 ± 7.0 | 0.2 ± 7.9 | -1.8 ± 6.8 | 1.4 ± 8.5 |
| Week 40 | 0.2 ± 6.7 | 1.4 ± 6.9 | 0.5 ± 6.5 | 3.3 ± 7.9 |
| Week 48 | 1.3 ± 8.0 | 0.3 ± 7.6 | 0.1 ± 6.2 | 4.5 ± 7.3 |
Cluster of differentiation 19 (CD19) was measured in cells per microliter (cells/µL).
| cells/µL | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 9.6 ± 56.7 | 12.3 ± 76.2 | 24.8 ± 71.0 | 63.4 ± 133.5 |
| Week 4 | -2.8 ± 46.3 | -31.2 ± 177.0 | 9.2 ± 60.5 | 82.8 ± 154.5 |
| Week 8 | -13.3 ± 72.9 | -29.4 ± 183.5 | 8.7 ± 70.8 | 19.4 ± 146.4 |
| Week 12 | -2.6 ± 83.4 | -48.1 ± 207.1 | -17.9 ± 77.8 | 53.2 ± 203.6 |
| Week 16 | -12.5 ± 84.3 | -50.1 ± 201.5 | -10.0 ± 92.4 | 13.2 ± 147.8 |
| Week 20 | -15.1 ± 86.0 | -75.4 ± 216.6 | -2.5 ± 57.1 | 2.7 ± 132.6 |
| Week 24 | -15.0 ± 89.3 | -77.2 ± 231.9 | -20.3 ± 72.0 | -1.1 ± 135.0 |
| Week 28 | -20.6 ± 106.7 | -69.6 ± 206.7 | -13.1 ± 84.5 | -13.0 ± 123.2 |
| Week 32 | -14.3 ± 106.3 | -75.8 ± 225.7 | -10.4 ± 93.0 | -20.9 ± 168.1 |
| Week 40 | -24.8 ± 103.3 | -68.6 ± 211.0 | -26.9 ± 83.0 | -46.9 ± 138.0 |
| Week 48 | -37.0 ± 132.7 | -82.4 ± 243.7 | -15.5 ± 83.2 | -41.2 ± 120.0 |
CD19/Lymphocytes was measured in percentages (%).
| % of CD19 per Leukocytes | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.3 ± 2.1 | -0.1 ± 3.0 | 1.0 ± 3.5 | 1.5 ± 5.9 |
| Week 4 | 0.0 ± 2.9 | -0.5 ± 3.7 | 0.7 ± 3.3 | 2.8 ± 5.7 |
| Week 8 | 0.1 ± 2.8 | -0.5 ± 4.2 | 0.7 ± 2.5 | 0.4 ± 6.4 |
| Week 12 | -0.2 ± 3.2 | -1.0 ± 3.9 | -0.4 ± 3.1 | 1.7 ± 7.9 |
| Week 16 | 0.0 ± 4.7 | -1.2 ± 5.0 | -0.4 ± 3.3 | 0.7 ± 5.9 |
| Week 20 | -0.4 ± 3.8 | -2.1 ± 6.2 | -0.3 ± 3.0 | -0.2 ± 6.9 |
| Week 24 | -0.9 ± 4.5 | -2.0 ± 6.5 | -0.6 ± 3.3 | -0.3 ± 7.3 |
| Week 28 | -1.2 ± 5.4 | -2.5 ± 5.9 | -1.1 ± 3.3 | -1.0 ± 6.6 |
| Week 32 | -0.4 ± 4.7 | -2.4 ± 5.5 | -0.6 ± 4.4 | -1.6 ± 6.3 |
| Week 40 | -1.2 ± 4.7 | -2.6 ± 5.4 | -1.9 ± 4.2 | -3.4 ± 6.7 |
| Week 48 | -1.2 ± 6.8 | -2.6 ± 7.2 | -1.6 ± 4.9 | -3.3 ± 6.2 |
Aspartate Aminotransferase was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.5 ± 8.8 | 0.2 ± 8.0 | 4.3 ± 43.1 | 0.0 ± 7.2 |
| Week 4 | -0.1 ± 11.2 | 0.2 ± 7.4 | -1.1 ± 7.6 | -1.9 ± 8.0 |
| Week 8 | -0.1 ± 8.7 | -1.5 ± 6.2 | 0.5 ± 13.0 | -1.1 ± 8.1 |
| Week 12 | 5.1 ± 27.0 | 0.9 ± 6.2 | -1.8 ± 10.0 | -2.9 ± 7.1 |
| Week 16 | 0.4 ± 7.7 | 0.0 ± 6.3 | -2.3 ± 11.6 | -2.8 ± 8.4 |
| Week 20 | 4.1 ± 24.1 | 1.0 ± 11.5 | -0.7 ± 13.8 | -3.8 ± 8.1 |
| Week 24 | 0.6 ± 11.8 | 1.6 ± 10.4 | -1.8 ± 11.5 | -3.8 ± 8.4 |
| Week 28 | 0.0 ± 12.3 | 0.0 ± 10.2 | -1.5 ± 11.1 | -3.4 ± 9.1 |
| Week 32 | -0.3 ± 11.0 | 0.3 ± 6.8 | -0.7 ± 12.9 | -3.4 ± 9.2 |
| Week 40 | -0.6 ± 10.2 | 0.1 ± 9.1 | -0.3 ± 11.5 | -1.5 ± 9.8 |
| Week 48 | 1.1 ± 10.8 | 0.1 ± 13.1 | 1.4 ± 13.4 | -2.1 ± 8.6 |
Alanine Aminotransferase was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 2.4 ± 14.1 | 2.6 ± 10.6 | 0.5 ± 11.1 | -0.1 ± 8.6 |
| Week 4 | 0.8 ± 9.9 | -0.5 ± 8.5 | 0.9 ± 7.4 | 0.3 ± 8.2 |
| Week 8 | 0.2 ± 10.2 | -0.8 ± 8.3 | 5.3 ± 28.8 | -0.6 ± 9.6 |
| Week 12 | 7.0 ± 21.3 | 0.8 ± 14.3 | -0.8 ± 8.1 | -0.1 ± 7.6 |
| Week 16 | 1.5 ± 13.3 | -0.4 ± 9.3 | 0.0 ± 10.3 | -1.1 ± 7.8 |
| Week 20 | 5.3 ± 23.6 | -0.2 ± 10.2 | 1.4 ± 10.8 | -3.7 ± 6.3 |
| Week 24 | 3.1 ± 20.9 | 0.5 ± 14.1 | 2.0 ± 12.0 | -2.8 ± 7.7 |
| Week 28 | 1.0 ± 13.9 | 0.7 ± 10.5 | -0.4 ± 9.3 | -2.7 ± 7.2 |
| Week 32 | 1.2 ± 13.4 | -0.5 ± 10.3 | 1.3 ± 10.8 | -3.2 ± 6.1 |
| Week 40 | -0.5 ± 13.4 | 2.6 ± 12.8 | 3.0 ± 12.9 | -0.7 ± 8.3 |
| Week 48 | 0.4 ± 11.5 | -1.2 ± 10.4 | 3.5 ± 17.0 | -1.1 ± 7.8 |
Alkaline Phosphatase was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 1.8 ± 10.7 | 2.4 ± 10.6 | 1.5 ± 8.0 | -3.6 ± 10.1 |
| Week 4 | -1.7 ± 9.7 | 0.7 ± 9.2 | -0.7 ± 8.4 | -4.7 ± 9.4 |
| Week 8 | 1.7 ± 12.9 | 2.4 ± 12.7 | 1.8 ± 15.6 | -6.1 ± 11.0 |
| Week 12 | 2.2 ± 11.6 | 4.2 ± 16.4 | 1.9 ± 12.9 | -4.4 ± 11.8 |
| Week 16 | 3.1 ± 10.7 | 2.7 ± 13.0 | 0.0 ± 10.4 | -6.7 ± 12.8 |
| Week 20 | 3.9 ± 14.0 | 1.4 ± 11.8 | 1.4 ± 11.8 | -7.4 ± 11.2 |
| Week 24 | 4.7 ± 15.0 | 3.7 ± 14.0 | 2.8 ± 11.6 | -2.7 ± 14.0 |
| Week 28 | 2.8 ± 14.0 | 3.1 ± 14.2 | 1.9 ± 9.5 | -2.1 ± 13.5 |
| Week 32 | 3.8 ± 14.6 | 2.7 ± 16.0 | 3.2 ± 12.1 | 1.0 ± 15.9 |
| Week 40 | 2.4 ± 17.1 | 1.3 ± 13.1 | 2.7 ± 13.0 | -3.0 ± 18.0 |
| Week 48 | 2.6 ± 13.3 | 4.0 ± 16.8 | 5.5 ± 12.8 | -4.5 ± 18.8 |
Gamma Glutamyl Transferase was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.3 ± 7.6 | 2.0 ± 11.5 | 8.8 ± 68.9 | -3.4 ± 24.3 |
| Week 4 | 2.1 ± 8.7 | -1.3 ± 8.8 | 2.7 ± 28.5 | -6.5 ± 35.5 |
| Week 8 | 3.5 ± 23.0 | 0.3 ± 10.5 | -2.8 ± 49.3 | -9.2 ± 43.3 |
| Week 12 | 4.1 ± 21.0 | 0.5 ± 13.4 | -5.1 ± 29.3 | -8.3 ± 46.1 |
| Week 16 | 6.5 ± 20.2 | 2.1 ± 12.5 | -6.1 ± 45.0 | -10.6 ± 47.7 |
| Week 20 | 3.5 ± 14.1 | 0.2 ± 13.4 | -3.7 ± 50.3 | -8.5 ± 50.5 |
| Week 24 | 7.1 ± 22.0 | 4.0 ± 18.7 | -0.4 ± 53.1 | -9.5 ± 47.2 |
| Week 28 | 4.6 ± 25.7 | 2.2 ± 18.3 | -7.0 ± 46.8 | 0.0 ± 23.1 |
| Week 32 | 4.4 ± 28.6 | 1.5 ± 16.7 | -5.9 ± 44.5 | -8.2 ± 37.4 |
| Week 40 | 3.4 ± 41.3 | 5.7 ± 32.4 | 0.4 ± 10.1 | -9.1 ± 45.3 |
| Week 48 | 1.8 ± 11.4 | 5.3 ± 23.9 | 4.7 ± 21.6 | -9.8 ± 44.5 |
Bilirubin was measured in micromols per liter (µmol/L).
| μmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.35 ± 2.72 | -0.48 ± 2.71 | 0.28 ± 2.38 | -0.78 ± 3.13 |
| Week 4 | 0.07 ± 2.50 | -0.18 ± 2.09 | -0.05 ± 2.14 | -0.79 ± 2.80 |
| Week 8 | -0.09 ± 2.66 | -0.69 ± 2.22 | -0.19 ± 2.13 | -0.23 ± 2.80 |
| Week 12 | -0.04 ± 2.60 | -0.70 ± 2.74 | 0.37 ± 2.17 | -0.33 ± 3.28 |
| Week 16 | 0.06 ± 2.41 | -0.45 ± 2.43 | -0.20 ± 2.71 | -0.51 ± 3.64 |
| Week 20 | -0.54 ± 2.89 | -0.38 ± 2.51 | 0.51 ± 2.81 | -0.30 ± 3.03 |
| Week 24 | 0.08 ± 2.75 | -0.14 ± 2.86 | 0.54 ± 2.18 | -0.38 ± 3.57 |
| Week 28 | -0.10 ± 2.98 | -0.26 ± 3.23 | 0.79 ± 2.71 | -0.82 ± 2.61 |
| Week 32 | 0.09 ± 2.75 | -0.38 ± 2.61 | 0.93 ± 3.18 | -0.38 ± 3.61 |
| Week 40 | -0.26 ± 3.70 | 0.07 ± 3.18 | 1.03 ± 2.35 | -0.15 ± 2.64 |
| Week 48 | 0.69 ± 3.57 | -0.50 ± 3.12 | 0.79 ± 3.04 | -0.20 ± 2.52 |
Direct Bilirubin was measured in micromols per liter (µmol/L).
| μmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.03 ± 0.92 | -0.06 ± 0.92 | 0.09 ± 1.12 | -0.24 ± 1.10 |
| Week 4 | 0.10 ± 1.03 | 0.03 ± 0.75 | -0.04 ± 0.82 | -0.10 ± 0.93 |
| Week 8 | 0.03 ± 0.91 | -0.18 ± 0.55 | -0.17 ± 0.86 | 0.03 ± 1.10 |
| Week 12 | 0.15 ± 0.99 | -0.07 ± 0.95 | -0.01 ± 1.06 | -0.05 ± 1.30 |
| Week 16 | 0.18 ± 0.81 | -0.01 ± 0.66 | -0.07 ± 1.04 | -0.01 ± 1.40 |
| Week 20 | -0.04 ± 0.95 | 0.07 ± 0.91 | 0.02 ± 0.94 | 0.00 ± 1.19 |
| Week 24 | 0.05 ± 1.10 | 0.14 ± 0.95 | 0.08 ± 1.02 | -0.08 ± 1.25 |
| Week 28 | 0.06 ± 1.06 | -0.06 ± 1.00 | 0.11 ± 0.80 | -0.06 ± 1.15 |
| Week 32 | 0.12 ± 1.16 | 0.05 ± 0.90 | 0.21 ± 1.21 | -0.04 ± 1.36 |
| Week 40 | 0.07 ± 1.31 | 0.03 ± 0.76 | 0.23 ± 1.00 | 0.07 ± 1.05 |
| Week 48 | 0.31 ± 1.34 | -0.05 ± 1.01 | 0.20 ± 1.25 | 0.08 ± 0.98 |
Lactate Dehydrogenase was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -3.3 ± 27.8 | -7.8 ± 21.2 | -5.9 ± 35.2 | -12.8 ± 24.8 |
| Week 4 | -3.0 ± 23.4 | -3.7 ± 37.0 | -5.6 ± 35.6 | -18.5 ± 34.1 |
| Week 8 | -5.7 ± 27.4 | -11.8 ± 31.5 | -9.2 ± 39.0 | -20.4 ± 37.4 |
| Week 12 | 3.0 ± 28.7 | -7.4 ± 34.6 | -11.1 ± 45.1 | -24.4 ± 39.0 |
| Week 16 | -2.2 ± 25.5 | -11.1 ± 29.9 | -10.6 ± 48.6 | -22.4 ± 43.3 |
| Week 20 | -0.7 ± 33.9 | -10.8 ± 37.0 | -9.9 ± 47.8 | -28.5 ± 32.1 |
| Week 24 | -4.5 ± 31.3 | -14.3 ± 31.5 | -14.6 ± 34.4 | -29.3 ± 32.2 |
| Week 28 | 0.0 ± 40.8 | -16.0 ± 40.9 | -13.2 ± 35.0 | -34.8 ± 36.9 |
| Week 32 | 5.0 ± 55.0 | -9.9 ± 43.4 | -8.1 ± 33.5 | -22.9 ± 40.6 |
| Week 40 | -1.6 ± 38.1 | -2.9 ± 41.1 | -8.0 ± 28.4 | -20.5 ± 40.1 |
| Week 48 | -8.8 ± 35.2 | -4.2 ± 54.3 | -1.5 ± 32.7 | -16.0 ± 36.3 |
Creatinine was measured in micromols per liter (µmol/L).
| μmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.9 ± 9.1 | -0.1 ± 8.0 | 1.5 ± 5.8 | 0.6 ± 7.2 |
| Week 4 | -0.8 ± 8.9 | -0.2 ± 9.3 | -0.6 ± 7.3 | -1.4 ± 8.2 |
| Week 8 | 0.5 ± 7.0 | 0.3 ± 7.6 | -0.5 ± 6.9 | 0.1 ± 8.4 |
| Week 12 | -0.3 ± 7.0 | 1.4 ± 7.5 | -0.4 ± 6.4 | -0.7 ± 8.2 |
| Week 16 | -0.1 ± 9.8 | 1.0 ± 8.2 | 0.7 ± 6.8 | -1.1 ± 9.4 |
| Week 20 | 0.7 ± 8.6 | 1.4 ± 10.2 | 0.8 ± 6.9 | -0.3 ± 7.7 |
| Week 24 | 0.0 ± 8.8 | 0.8 ± 8.8 | 0.3 ± 6.6 | 0.9 ± 9.7 |
| Week 28 | 2.5 ± 10.0 | 2.7 ± 10.0 | 1.0 ± 7.8 | -0.9 ± 7.8 |
| Week 32 | 5.5 ± 35.7 | 0.5 ± 8.1 | 3.6 ± 7.8 | 1.6 ± 11.2 |
| Week 40 | 2.3 ± 9.5 | 2.2 ± 8.5 | 3.9 ± 6.0 | 3.0 ± 8.4 |
| Week 48 | 1.9 ± 10.6 | 0.7 ± 7.6 | 2.5 ± 5.2 | 2.9 ± 9.8 |
Urea Nitrogen was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.28 ± 1.55 | -0.09 ± 1.23 | -0.05 ± 1.32 | -0.02 ± 1.31 |
| Week 4 | -0.07 ± 1.21 | -0.33 ± 1.52 | -0.14 ± 1.20 | 0.04 ± 1.19 |
| Week 8 | 0.06 ± 1.25 | -0.26 ± 1.22 | -0.19 ± 1.07 | 0.17 ± 1.59 |
| Week 12 | 0.03 ± 1.13 | -0.39 ± 1.31 | -0.29 ± 1.17 | -0.22 ± 1.15 |
| Week 16 | 0.19 ± 1.35 | -0.18 ± 1.40 | 0.19 ± 1.49 | -0.03 ± 1.41 |
| Week 20 | -0.18 ± 1.29 | -0.20 ± 1.33 | -0.25 ± 1.22 | -0.16 ± 1.08 |
| Week 24 | 0.08 ± 1.69 | -0.44 ± 1.38 | -0.13 ± 1.18 | -0.09 ± 1.50 |
| Week 28 | 0.13 ± 1.38 | 0.03 ± 1.61 | -0.23 ± 1.26 | -0.22 ± 1.14 |
| Week 32 | 0.40 ± 2.37 | -0.30 ± 1.65 | 0.21 ± 1.17 | 0.10 ± 1.43 |
| Week 40 | 0.29 ± 1.54 | 0.10 ± 1.73 | 0.21 ± 1.20 | 0.14 ± 1.43 |
| Week 48 | 0.05 ± 1.22 | -0.31 ± 1.54 | 0.23 ± 1.38 | -0.02 ± 1.56 |
Sodium was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.1 ± 1.9 | -0.4 ± 2.4 | 0.1 ± 1.6 | 0.0 ± 2.2 |
| Week 4 | -0.3 ± 2.0 | -0.6 ± 2.1 | 0.3 ± 2.1 | -0.1 ± 2.4 |
| Week 8 | 0.1 ± 2.2 | -0.4 ± 2.4 | 0.3 ± 2.2 | 0.1 ± 2.3 |
| Week 12 | -0.3 ± 2.0 | -0.5 ± 2.0 | 0.2 ± 2.0 | 0.1 ± 2.3 |
| Week 16 | -0.4 ± 2.3 | -0.2 ± 1.9 | 0.0 ± 2.0 | -0.2 ± 2.3 |
| Week 20 | 0.3 ± 2.2 | -0.8 ± 2.2 | -0.1 ± 2.0 | -0.5 ± 2.4 |
| Week 24 | -0.1 ± 2.5 | -0.4 ± 2.2 | 0.0 ± 2.2 | -0.3 ± 2.1 |
| Week 28 | 0.0 ± 1.9 | -0.4 ± 2.4 | 0.2 ± 1.9 | 0.1 ± 2.3 |
| Week 32 | 0.0 ± 2.3 | -0.8 ± 3.2 | 0.1 ± 2.1 | 0.2 ± 2.2 |
| Week 40 | -0.1 ± 2.2 | -1.2 ± 2.2 | -0.1 ± 1.6 | -0.3 ± 2.4 |
| Week 48 | -0.4 ± 2.0 | -1.1 ± 2.6 | -0.5 ± 1.7 | 0.2 ± 2.3 |
Potassium was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.04 ± 0.45 | 0.15 ± 0.40 | 0.00 ± 0.36 | -0.03 ± 0.37 |
| Week 4 | 0.06 ± 0.44 | 0.08 ± 0.35 | -0.07 ± 0.41 | -0.12 ± 0.40 |
| Week 8 | -0.04 ± 0.40 | 0.11 ± 0.38 | 0.00 ± 0.35 | -0.07 ± 0.40 |
| Week 12 | -0.01 ± 0.33 | 0.02 ± 0.31 | -0.07 ± 0.41 | -0.12 ± 0.34 |
| Week 16 | -0.01 ± 0.34 | 0.16 ± 0.33 | -0.09 ± 0.42 | -0.05 ± 0.33 |
| Week 20 | 0.04 ± 0.38 | 0.14 ± 0.33 | -0.04 ± 0.46 | -0.08 ± 0.37 |
| Week 24 | 0.06 ± 0.43 | 0.07 ± 0.39 | 0.03 ± 0.33 | -0.11 ± 0.37 |
| Week 28 | 0.09 ± 0.43 | 0.12 ± 0.47 | 0.06 ± 0.42 | 0.03 ± 0.45 |
| Week 32 | 0.03 ± 0.44 | 0.07 ± 0.44 | 0.10 ± 0.46 | -0.05 ± 0.38 |
| Week 40 | 0.06 ± 0.33 | 0.16 ± 0.51 | 0.16 ± 0.39 | -0.06 ± 0.37 |
| Week 48 | -0.01 ± 0.30 | 0.00 ± 0.30 | -0.02 ± 0.39 | -0.07 ± 0.40 |
Calcium was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.008 ± 0.104 | -0.001 ± 0.103 | 0.004 ± 0.088 | -0.008 ± 0.092 |
| Week 4 | 0.007 ± 0.108 | -0.018 ± 0.099 | -0.018 ± 0.090 | -0.001 ± 0.086 |
| Week 8 | -0.006 ± 0.093 | -0.033 ± 0.117 | -0.014 ± 0.106 | -0.003 ± 0.089 |
| Week 12 | 0.006 ± 0.108 | -0.011 ± 0.121 | -0.013 ± 0.097 | -0.004 ± 0.111 |
| Week 16 | -0.025 ± 0.106 | -0.004 ± 0.088 | -0.013 ± 0.095 | -0.024 ± 0.119 |
| Week 20 | -0.036 ± 0.116 | -0.020 ± 0.084 | -0.015 ± 0.108 | 0.005 ± 0.080 |
| Week 24 | -0.027 ± 0.106 | -0.026 ± 0.094 | -0.012 ± 0.095 | 0.007 ± 0.100 |
| Week 28 | -0.031 ± 0.121 | -0.039 ± 0.091 | -0.016 ± 0.113 | -0.014 ± 0.092 |
| Week 32 | 0.003 ± 0.098 | -0.043 ± 0.099 | 0.019 ± 0.107 | -0.001 ± 0.105 |
| Week 40 | -0.027 ± 0.114 | -0.022 ± 0.115 | 0.006 ± 0.115 | -0.012 ± 0.105 |
| Week 48 | -0.013 ± 0.096 | -0.037 ± 0.119 | -0.004 ± 0.104 | -0.017 ± 0.110 |
Phosphate was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.044 ± 0.163 | 0.032 ± 0.192 | -0.047 ± 0.230 | 0.033 ± 0.168 |
| Week 4 | -0.004 ± 0.162 | -0.029 ± 0.185 | -0.070 ± 0.187 | 0.020 ± 0.163 |
| Week 8 | 0.006 ± 0.178 | -0.063 ± 0.225 | -0.028 ± 0.207 | 0.051 ± 0.187 |
| Week 12 | 0.029 ± 0.159 | -0.004 ± 0.149 | -0.015 ± 0.236 | 0.045 ± 0.183 |
| Week 16 | -0.010 ± 0.186 | 0.012 ± 0.182 | -0.025 ± 0.195 | 0.005 ± 0.178 |
| Week 20 | -0.030 ± 0.208 | -0.037 ± 0.244 | -0.031 ± 0.177 | 0.013 ± 0.187 |
| Week 24 | -0.013 ± 0.181 | -0.042 ± 0.160 | -0.040 ± 0.229 | 0.035 ± 0.200 |
| Week 28 | -0.024 ± 0.189 | 0.008 ± 0.238 | -0.031 ± 0.232 | 0.037 ± 0.184 |
| Week 32 | -0.002 ± 0.217 | -0.056 ± 0.223 | 0.015 ± 0.220 | 0.030 ± 0.190 |
| Week 40 | 0.018 ± 0.207 | 0.009 ± 0.196 | -0.022 ± 0.208 | 0.034 ± 0.224 |
| Week 48 | 0.032 ± 0.183 | -0.012 ± 0.167 | -0.044 ± 0.214 | 0.035 ± 0.190 |
Cholesterol was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.00 ± 0.49 | -0.07 ± 0.46 | -0.06 ± 0.51 | -0.19 ± 0.47 |
| Week 4 | -0.08 ± 0.49 | -0.03 ± 0.46 | -0.07 ± 0.68 | -0.07 ± 0.57 |
| Week 8 | -0.09 ± 0.57 | -0.07 ± 0.46 | -0.15 ± 0.81 | -0.17 ± 0.59 |
| Week 12 | -0.14 ± 0.72 | -0.16 ± 0.61 | -0.23 ± 0.68 | -0.10 ± 0.75 |
| Week 16 | -0.16 ± 0.80 | -0.16 ± 0.66 | -0.35 ± 0.80 | -0.27 ± 0.72 |
| Week 20 | -0.27 ± 0.77 | -0.22 ± 0.60 | -0.42 ± 0.81 | -0.23 ± 0.85 |
| Week 24 | -0.12 ± 0.87 | -0.17 ± 0.66 | -0.28 ± 0.96 | -0.16 ± 0.78 |
| Week 28 | -0.17 ± 0.89 | -0.37 ± 0.63 | -0.35 ± 0.97 | -0.29 ± 0.80 |
| Week 32 | -0.13 ± 0.86 | -0.22 ± 0.63 | -0.16 ± 0.83 | -0.15 ± 0.81 |
| Week 40 | -0.34 ± 0.87 | -0.25 ± 0.80 | -0.19 ± 0.77 | -0.13 ± 1.15 |
| Week 48 | -0.40 ± 0.80 | -0.36 ± 0.74 | -0.23 ± 0.97 | -0.18 ± 1.09 |
Triglycerides was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.176 ± 1.593 | 0.046 ± 0.683 | 0.110 ± 0.855 | 0.183 ± 0.751 |
| Week 4 | -0.189 ± 1.212 | -0.004 ± 0.510 | -0.030 ± 0.471 | 0.084 ± 0.529 |
| Week 8 | -0.182 ± 1.554 | 0.076 ± 0.582 | -0.084 ± 0.498 | 0.046 ± 0.585 |
| Week 12 | -0.265 ± 1.445 | 0.088 ± 0.713 | 0.063 ± 0.578 | 0.009 ± 0.514 |
| Week 16 | -0.164 ± 1.345 | 0.099 ± 1.488 | 0.142 ± 0.580 | 0.112 ± 1.035 |
| Week 20 | -0.233 ± 1.391 | -0.104 ± 0.837 | 0.008 ± 0.622 | -0.060 ± 0.707 |
| Week 24 | -0.263 ± 1.515 | -0.045 ± 0.774 | -0.013 ± 0.608 | -0.030 ± 0.707 |
| Week 28 | -0.013 ± 1.559 | -0.125 ± 0.782 | -0.043 ± 0.423 | -0.036 ± 0.663 |
| Week 32 | -0.260 ± 1.418 | 0.045 ± 0.717 | 0.057 ± 0.532 | 0.112 ± 0.718 |
| Week 40 | -0.134 ± 1.175 | -0.159 ± 0.765 | 0.177 ± 0.821 | 0.022 ± 0.644 |
| Week 48 | -0.242 ± 1.516 | -0.149 ± 0.758 | 0.114 ± 0.507 | 0.054 ± 0.752 |
Protein was measured in grams per liter (g/L).
| g/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.2 ± 3.7 | -1.2 ± 4.0 | -1.0 ± 4.2 | -1.1 ± 3.8 |
| Week 4 | -1.5 ± 4.4 | -1.6 ± 4.2 | -1.5 ± 4.7 | -1.7 ± 4.4 |
| Week 8 | -1.1 ± 4.4 | -2.1 ± 4.1 | -1.8 ± 5.7 | -2.0 ± 3.9 |
| Week 12 | -0.8 ± 3.8 | -1.3 ± 4.7 | -1.4 ± 5.2 | -1.2 ± 5.8 |
| Week 16 | -1.2 ± 5.2 | -0.3 ± 4.1 | -2.3 ± 5.6 | -3.8 ± 5.0 |
| Week 20 | -2.7 ± 6.0 | -1.6 ± 4.6 | -2.6 ± 4.7 | -3.1 ± 5.4 |
| Week 24 | -2.2 ± 7.5 | -1.8 ± 4.6 | -1.8 ± 5.5 | -2.0 ± 4.7 |
| Week 28 | -3.1 ± 7.4 | -2.4 ± 4.6 | -2.5 ± 5.7 | -3.6 ± 6.4 |
| Week 32 | -1.4 ± 6.9 | -1.5 ± 5.7 | -0.8 ± 5.0 | -1.9 ± 6.4 |
| Week 40 | -2.2 ± 6.5 | -0.9 ± 5.0 | -1.8 ± 5.3 | -2.6 ± 6.1 |
| Week 48 | -2.3 ± 6.2 | -2.4 ± 5.9 | -0.9 ± 5.1 | -3.4 ± 6.4 |
Albumin was measured in grams per liter (g/L).
| g/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.1 ± 2.1 | -0.4 ± 2.4 | -0.5 ± 2.4 | -0.5 ± 1.9 |
| Week 4 | -0.5 ± 2.4 | -0.4 ± 2.3 | -0.2 ± 2.4 | -0.3 ± 1.9 |
| Week 8 | -0.3 ± 2.3 | -0.3 ± 2.5 | -0.3 ± 3.0 | 0.1 ± 2.2 |
| Week 12 | -0.1 ± 2.2 | 0.2 ± 2.7 | 0.2 ± 2.7 | 0.7 ± 3.0 |
| Week 16 | 0.0 ± 2.5 | 1.0 ± 2.5 | 0.1 ± 2.9 | -0.2 ± 2.9 |
| Week 20 | -0.7 ± 2.7 | 0.1 ± 2.7 | 0.4 ± 2.4 | 0.4 ± 2.2 |
| Week 24 | -0.1 ± 2.9 | 0.0 ± 2.1 | 0.4 ± 2.4 | 1.2 ± 2.7 |
| Week 28 | -0.7 ± 3.0 | -0.4 ± 2.3 | 0.1 ± 2.9 | 0.1 ± 2.6 |
| Week 32 | 0.6 ± 2.8 | -0.1 ± 3.0 | 0.9 ± 3.2 | 0.7 ± 2.8 |
| Week 40 | 0.1 ± 2.8 | -0.1 ± 2.9 | 0.2 ± 2.6 | 0.3 ± 3.0 |
| Week 48 | 0.1 ± 2.8 | -0.7 ± 3.0 | 0.2 ± 3.0 | -0.8 ± 3.5 |
Glucose was measured in millimoles per liter (mmol/L).
| mmol/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | 0.18 ± 0.75 | 0.26 ± 0.70 | 0.09 ± 0.78 | 0.13 ± 1.28 |
| Week 4 | 0.04 ± 0.71 | 0.03 ± 0.70 | -0.04 ± 0.90 | 0.11 ± 1.10 |
| Week 8 | 0.17 ± 0.66 | 0.12 ± 0.90 | 0.23 ± 0.95 | 0.12 ± 1.16 |
| Week 12 | -0.08 ± 0.69 | 0.08 ± 0.66 | -0.13 ± 0.79 | -0.15 ± 0.99 |
| Week 16 | 0.11 ± 0.77 | 0.06 ± 0.63 | 0.16 ± 0.92 | -0.18 ± 1.47 |
| Week 20 | 0.16 ± 0.85 | 0.20 ± 0.84 | 0.13 ± 0.83 | -0.08 ± 1.01 |
| Week 24 | -0.07 ± 0.85 | 0.05 ± 0.49 | -0.09 ± 0.73 | -0.22 ± 1.06 |
| Week 28 | 0.22 ± 1.01 | 0.09 ± 0.76 | -0.01 ± 0.74 | 0.07 ± 1.22 |
| Week 32 | -0.04 ± 0.72 | -0.07 ± 0.63 | -0.08 ± 0.65 | 0.06 ± 1.10 |
| Week 40 | -0.05 ± 0.62 | 0.08 ± 0.71 | -0.09 ± 0.68 | -0.08 ± 1.07 |
| Week 48 | -0.14 ± 0.78 | -0.11 ± 0.61 | -0.06 ± 0.64 | -0.14 ± 1.25 |
Lipase, Pancreatic was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -1.1 ± 10.5 | 2.2 ± 11.9 | 0.1 ± 9.2 | -0.2 ± 7.5 |
| Week 4 | -2.1 ± 9.8 | 0.9 ± 9.1 | 0.1 ± 10.6 | -1.2 ± 10.0 |
| Week 8 | -3.1 ± 9.2 | 3.7 ± 11.8 | 2.0 ± 20.0 | -1.8 ± 10.3 |
| Week 12 | -0.5 ± 8.7 | 1.0 ± 11.1 | -0.7 ± 13.4 | -0.6 ± 9.6 |
| Week 16 | 0.4 ± 7.4 | 2.7 ± 8.4 | 0.5 ± 11.3 | -0.2 ± 11.8 |
| Week 20 | -0.6 ± 10.4 | 2.1 ± 8.0 | -0.9 ± 9.0 | -1.7 ± 9.3 |
| Week 24 | -0.5 ± 11.0 | -0.1 ± 9.1 | -0.1 ± 8.1 | 1.2 ± 11.8 |
| Week 28 | 1.6 ± 13.1 | 1.7 ± 10.5 | 0.5 ± 11.9 | 1.7 ± 14.1 |
| Week 32 | 1.1 ± 15.1 | 1.0 ± 11.0 | 1.2 ± 10.6 | 3.8 ± 21.6 |
| Week 40 | 1.2 ± 11.0 | 1.3 ± 7.0 | -0.3 ± 8.9 | 2.5 ± 8.9 |
| Week 48 | 1.4 ± 10.1 | 2.2 ± 10.0 | 0.3 ± 10.7 | 3.7 ± 10.2 |
Creatine Kinase was measured in units per liter (U/L).
| U/L | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -3.0 ± 67.1 | -2.2 ± 55.6 | -2.2 ± 18.2 | 0.1 ± 46.5 |
| Week 4 | 29.6 ± 218.4 | -6.2 ± 54.8 | 3.2 ± 22.0 | -16.9 ± 56.5 |
| Week 8 | -4.9 ± 56.9 | -8.5 ± 52.7 | -1.5 ± 23.6 | -4.6 ± 122.1 |
| Week 12 | -6.3 ± 57.5 | -8.4 ± 85.8 | -3.0 ± 22.4 | -29.4 ± 80.7 |
| Week 16 | 0.9 ± 59.4 | -11.5 ± 105.1 | -7.5 ± 22.2 | -23.2 ± 106.3 |
| Week 20 | -8.2 ± 60.0 | 5.9 ± 149.1 | -3.5 ± 22.2 | -33.4 ± 95.3 |
| Week 24 | -6.4 ± 48.6 | -5.4 ± 123.7 | -2.6 ± 27.4 | -27.7 ± 98.9 |
| Week 28 | -1.5 ± 67.3 | -19.1 ± 131.5 | -0.7 ± 25.4 | -36.7 ± 103.8 |
| Week 32 | 2.0 ± 67.0 | -10.0 ± 167.0 | 34.0 ± 222.1 | -24.2 ± 91.2 |
| Week 40 | 9.9 ± 109.1 | -20.4 ± 131.4 | -2.7 ± 25.4 | -16.3 ± 106.4 |
| Week 48 | 7.8 ± 67.3 | -20.4 ± 138.3 | -3.6 ± 25.5 | -33.4 ± 106.5 |
| pH | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.01 ± 0.66 | 0.03 ± 0.62 | -0.07 ± 0.67 | 0.15 ± 0.78 |
| Week 4 | 0.10 ± 0.77 | 0.15 ± 0.52 | 0.06 ± 0.72 | 0.16 ± 0.74 |
| Week 8 | -0.12 ± 0.79 | 0.00 ± 0.62 | -0.08 ± 0.56 | -0.04 ± 0.65 |
| Week 12 | 0.00 ± 0.81 | 0.15 ± 0.69 | 0.03 ± 0.79 | 0.20 ± 0.83 |
| Week 16 | -0.02 ± 0.61 | 0.00 ± 0.51 | -0.09 ± 0.81 | 0.11 ± 0.69 |
| Week 20 | -0.11 ± 0.75 | -0.01 ± 0.59 | 0.06 ± 0.58 | 0.07 ± 0.88 |
| Week 24 | 0.03 ± 0.85 | -0.01 ± 0.46 | -0.11 ± 0.81 | 0.02 ± 0.81 |
| Week 28 | -0.13 ± 0.84 | -0.06 ± 0.57 | -0.05 ± 0.73 | -0.01 ± 0.69 |
| Week 32 | -0.02 ± 0.75 | -0.03 ± 0.55 | -0.18 ± 0.66 | 0.09 ± 0.86 |
| Week 40 | -0.14 ± 0.81 | 0.19 ± 0.66 | -0.21 ± 0.81 | -0.07 ± 0.62 |
| Week 48 | -0.11 ± 0.66 | 0.06 ± 0.73 | -0.11 ± 0.74 | -0.08 ± 0.72 |
| % of Erythrocytes per HPF | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -6.8 ± 53.7 | 0.1 ± 8.4 | 0.2 ± 2.4 | 0.9 ± 7.9 |
| Week 4 | -8.7 ± 52.6 | -0.8 ± 4.1 | 1.4 ± 10.5 | -0.6 ± 3.2 |
| Week 8 | -8.7 ± 53.5 | -0.3 ± 6.9 | 0.4 ± 6.1 | 0.0 ± 6.8 |
| Week 12 | -8.6 ± 52.6 | 1.3 ± 17.4 | -0.4 ± 2.4 | 17.4 ± 118.5 |
| Week 16 | -5.7 ± 48.0 | -1.3 ± 4.1 | -0.6 ± 2.6 | -0.5 ± 5.5 |
| Week 20 | -7.7 ± 53.7 | -1.0 ± 3.5 | -0.1 ± 3.9 | -0.6 ± 4.4 |
| Week 24 | -7.2 ± 53.5 | -1.2 ± 3.9 | -0.3 ± 2.3 | -0.9 ± 4.6 |
| Week 28 | -7.6 ± 51.3 | -1.3 ± 4.2 | -0.7 ± 2.9 | 3.0 ± 16.9 |
| Week 32 | -8.5 ± 52.5 | 4.9 ± 41.8 | 0.0 ± 3.9 | 0.1 ± 4.5 |
| Week 40 | -9.1 ± 53.2 | 3.5 ± 18.8 | -0.5 ± 3.5 | 0.4 ± 5.4 |
| Week 48 | -9.7 ± 56.3 | -0.4 ± 5.4 | 1.9 ± 15.5 | 0.1 ± 4.0 |
| % of Leukocytes per HPF | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Week 2 | -0.1 ± 11.4 | -1.4 ± 8.1 | -0.8 ± 2.9 | 2.9 ± 13.7 |
| Week 4 | -0.2 ± 9.0 | -0.6 ± 8.5 | -0.7 ± 4.5 | 3.0 ± 12.6 |
| Week 8 | -1.2 ± 10.4 | 4.8 ± 29.3 | -0.3 ± 6.8 | 3.0 ± 14.4 |
| Week 12 | -1.1 ± 11.3 | 4.4 ± 42.2 | -1.3 ± 4.2 | 2.7 ± 13.9 |
| Week 16 | 0.1 ± 9.6 | -1.6 ± 12.5 | -0.2 ± 9.6 | 1.8 ± 12.9 |
| Week 20 | -0.1 ± 10.1 | 3.7 ± 13.3 | 0.4 ± 9.8 | 1.7 ± 4.0 |
| Week 24 | -1.0 ± 10.9 | 10.7 ± 52.1 | -0.7 ± 4.5 | 0.4 ± 4.5 |
| Week 28 | -0.2 ± 9.6 | 2.4 ± 9.7 | -1.1 ± 4.4 | 2.0 ± 10.1 |
| Week 32 | -0.6 ± 10.8 | -0.5 ± 13.5 | -1.0 ± 5.4 | 4.1 ± 15.7 |
| Week 40 | -1.6 ± 10.4 | 2.2 ± 19.8 | 1.4 ± 7.7 | 6.8 ± 30.9 |
| Week 48 | -0.3 ± 8.9 | 10.8 ± 71.9 | -1.0 ± 4.0 | 0.8 ± 5.3 |
Collected over Adverse events were collected from Baseline (Week 1) until end of the study (Week 48). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOC + Placebo iv Q4W (SS) | 0/45 (0%) | 6/45 (13.3%) | 19/45 (42.2%) |
| SOC + DZP 6mg/kg iv Q4W (SS) | 0/45 (0%) | 5/45 (11.1%) | 23/45 (51.1%) |
| SOC + DZP 24mg/kg iv Q4W (SS) | 0/45 (0%) | 6/45 (13.3%) | 22/45 (48.9%) |
| SOC + DZP 45mg/kg iv Q4W (SS) | 0/47 (0%) | 5/47 (10.6%) | 21/47 (44.7%) |
| Event | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 2/45 | 0/45 | 0/45 | 1/47 |
| AnaemiaBlood and lymphatic system disorders | 0/45 | 0/45 | 1/45 | 0/47 |
| Autoimmune haemolytic anaemiaBlood and lymphatic system disorders | 0/45 | 1/45 | 0/45 | 0/47 |
| CellulitisInfections and infestations | 1/45 | 0/45 | 1/45 | 0/47 |
| Herpes zosterInfections and infestations | 1/45 | 1/45 | 0/45 | 0/47 |
| InfluenzaInfections and infestations | 1/45 | 0/45 | 0/45 | 0/47 |
| Pseudomonal bacteraemiaInfections and infestations | 0/45 | 0/45 | 1/45 | 0/47 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/45 | 1/45 | 0/45 | 0/47 |
| Lupus nephritisRenal and urinary disorders | 0/45 | 1/45 | 0/45 | 1/47 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/45 | 0/45 | 1/45 | 0/47 |
| Event | SOC + Placebo iv Q4W (SS) | SOC + DZP 6mg/kg iv Q4W (SS) | SOC + DZP 24mg/kg iv Q4W (SS) | SOC + DZP 45mg/kg iv Q4W (SS) |
|---|---|---|---|---|
| DyspepsiaGastrointestinal disorders | 5/45 | 1/45 | 0/45 | 0/47 |
| NasopharyngitisInfections and infestations | 2/45 | 5/45 | 5/45 | 4/47 |
| HeadacheNervous system disorders | 5/45 | 5/45 | 4/45 | 2/47 |
| Upper respiratory tract infectionInfections and infestations | 4/45 | 4/45 | 3/45 | 5/47 |
| DiarrhoeaGastrointestinal disorders | 2/45 | 4/45 | 3/45 | 3/47 |
| PharyngitisInfections and infestations | 1/45 | 4/45 | 4/45 | 3/47 |
| Urinary tract infectionInfections and infestations | 2/45 | 4/45 | 2/45 | 2/47 |
| Back painMusculoskeletal and connective tissue disorders | 2/45 | 4/45 | 0/45 | 2/47 |
| NauseaGastrointestinal disorders | 2/45 | 1/45 | 3/45 | 1/47 |
| BronchitisInfections and infestations | 0/45 | 3/45 | 1/45 | 2/47 |
Baseline Characteristics refer to the Safety Set which consisted of all study participants who were randomized and received at least 1 dose (any amount) of study drug.
| Age, Categorical(Participants) | SOC + Placebo iv Q4W | SOC + DZP 6mg/kg iv Q4W | SOC + DZP 24mg/kg iv Q4W | SOC + DZP 45mg/kg iv Q4W | Total Title |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 44 | 44 | 44 | 46 | 178 |
| >=65 years | 1 | 1 | 1 | 1 | 4 |
| Age, Continuous(years) | SOC + Placebo iv Q4W | SOC + DZP 6mg/kg iv Q4W | SOC + DZP 24mg/kg iv Q4W | SOC + DZP 45mg/kg iv Q4W | Total Title |
|---|---|---|---|---|---|
| Mean | 43.50 ± 12.79 | 40.81 ± 11.55 | 42.77 ± 10.42 | 38.94 ± 12.92 | 41.48 ± 12.01 |
| Sex: Female, Male(Participants) | SOC + Placebo iv Q4W | SOC + DZP 6mg/kg iv Q4W | SOC + DZP 24mg/kg iv Q4W | SOC + DZP 45mg/kg iv Q4W | Total Title |
|---|---|---|---|---|---|
| Female | 41 | 42 | 40 | 43 | 166 |
| Male | 4 | 3 | 5 | 4 | 16 |
| Race/Ethnicity, Customized(Participants) | SOC + Placebo iv Q4W | SOC + DZP 6mg/kg iv Q4W | SOC + DZP 24mg/kg iv Q4W | SOC + DZP 45mg/kg iv Q4W | Total Title |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 1 | 1 | 5 |
| Asian | 1 | 0 | 1 | 0 | 2 |
| Black | 1 | 4 | 1 | 6 | 12 |
| White | 27 | 26 | 33 | 27 | 113 |
| Other/Mixed | 14 | 14 | 9 | 13 | 50 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in May 2018, 23 months.
Results were first posted in Jun 2021, 3 years after primary completion. A results delay was requested in Jun 2019.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 23 months is below that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapirolizumab pegol
Lupus Erythematosus, Systemic →